← Find more feeds

chugai-pharm.co.jp

Chugai Pharmaceutical: News Releases

Get the latest updates from Chugai Pharmaceutical: News Releases directly as they happen.

Follow now 166 followers

Latest posts

Last updated 12 days ago

Chugai and Gero Enter into Joint Research and License Agreement to Develop Novel Therapies for Age-Related Diseases

12 days ago

Read full

Chugai Files for Additional Tumor-Agnostic Indication of Alecensa for ALK Fusion / Rearrangement Gene-Positive Solid Tumors Including Pediatric Patients

23 days ago

Read full

Eli Lilly’s Announcement Regarding Oral GLP-1 Orforglipron (Results of Phase III ACHIEVE-1 for Type 2 Diabetes Published in The New England Journal of Medicine)

26 days ago

Read full

Phase I/II Study in Hemophilia A Suggests NXT007 May Have the Potential to Provide Hemostatic Normalization

26 days ago

Read full

Roche Announces Global Phase III SUNMO Study Data for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (Combination Therapy with Lunsumio and Polivy)

26 days ago

Read full

Roche Announces New Safety Information of Elevidys for Non-Ambulatory Duchenne Muscular Dystrophy

about 1 month ago

Read full

Galderma’s Announcement Regarding NEMLUVIO (New Long Term Data Presentation in Atopic Dermatitis)

about 1 month ago

Read full

Verastem Oncology’s Announcement Regarding AVMAPKI (Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma)

about 2 months ago

Read full

Positive Results from Phase III TALENTACE Study of Tecentriq and Avastin for Unresectable Hepatocellular Carcinoma

about 2 months ago

Read full

Chugai Obtains First Regulatory Approval in Japan for Vabysmo for Additional Indication of Angioid Streaks, a Cause of Vision Loss

2 months ago

Read full

PiaSky Approved in Taiwan as First Subcutaneous Treatment for Paroxysmal Nocturnal Hemoglobinuria

2 months ago

Read full

Chugai Files for Additional Indication of Tecentriq for the Treatment of Thymic Carcinoma

2 months ago

Read full

Or log in

Everything you care about in one place

Chugai Pharmaceutical: News Releases

Latest posts

Chugai and Gero Enter into Joint Research and License Agreement to Develop Novel Therapies for Age-Related Diseases

Chugai Files for Additional Tumor-Agnostic Indication of Alecensa for ALK Fusion / Rearrangement Gene-Positive Solid Tumors Including Pediatric Patients

Eli Lilly’s Announcement Regarding Oral GLP-1 Orforglipron (Results of Phase III ACHIEVE-1 for Type 2 Diabetes Published in The New England Journal of Medicine)

Phase I/II Study in Hemophilia A Suggests NXT007 May Have the Potential to Provide Hemostatic Normalization

Roche Announces Global Phase III SUNMO Study Data for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (Combination Therapy with Lunsumio and Polivy)

Roche Announces New Safety Information of Elevidys for Non-Ambulatory Duchenne Muscular Dystrophy

Galderma’s Announcement Regarding NEMLUVIO (New Long Term Data Presentation in Atopic Dermatitis)

Verastem Oncology’s Announcement Regarding AVMAPKI (Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma)

Positive Results from Phase III TALENTACE Study of Tecentriq and Avastin for Unresectable Hepatocellular Carcinoma

Chugai Obtains First Regulatory Approval in Japan for Vabysmo for Additional Indication of Angioid Streaks, a Cause of Vision Loss

PiaSky Approved in Taiwan as First Subcutaneous Treatment for Paroxysmal Nocturnal Hemoglobinuria

Chugai Files for Additional Indication of Tecentriq for the Treatment of Thymic Carcinoma

Try Feeder for free